Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

Next Previous
Trial Profile

Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Natalizumab (Primary) ; Methylprednisolone; Prednisolone
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Feb 2018 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
    • 02 Feb 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top